Sartorius Stedim Biotech SA 2007 IR
The report details the first annual performance of Sartorius Stedim Biotech following the merger of Sartorius's Biotechnology Division and Stedim S.A. in June 2007. The company achieved pro forma sales revenue of •375.9 million and an underlying pro forma EBITA of •49.7 million. Key highlights include the successful integration of global sales and supply chain structures, the opening of a new laboratory building in Goettingen, and the acquisition of Toha Plast GmbH to secure plastics processing expertise. Additionally, the company advanced its environmental management by increasing plastics recycling at its Aubagne site to approximately 65%.
Company: Sartorius Stedim Biotech SA
Sector: Manufacturing
Country: France
Year: 2007
Type: IR
Pages: 161
Back to company
Sartorius Stedim Biotech SA
Reference Document
The report details the first annual performance of Sartorius Stedim Biotech following the merger of Sartorius's Biotechnology Division and Stedim S.A. in June 2007. The company achieved pro forma sales revenue of •375.9 million and an underlying pro forma EBITA of •49.7 million. Key highlights include the successful integration of global sales and supply chain structures, the opening of a new laboratory building in Goettingen, and the acquisition of Toha Plast GmbH to secure plastics processing expertise. Additionally, the company advanced its environmental management by increasing plastics recycling at its Aubagne site to approximately 65%.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2007
Reporting Period
Apr 1, 2007 - Dec 31, 2007
Fiscal Year
2007
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees